IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Advanced Malignant Mesothelioma Epithelial Mesothelioma Recurrent Malignant Mesothelioma Sarcomatous Mesothelioma | Biological: rilotumumab Drug: cisplatin Drug: pemetrexed disodium Other: laboratory biomarker analysis | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma |
- Progression-free survival [ Time Frame: From registration to clinical evidence of disease progression or death without progression, assessed up to 3 years ]
- Toxicity defined as a grade 4 hemorrhagic event or a grade 5 event [ Time Frame: Up to 30 days after completion of study treatment ]Graded using the NCI CTCAE.
| Enrollment: | 0 |
| Study Start Date: | April 2010 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment (rilotumumab, cisplatin, pemetrexed disodium)
Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
|
Biological: rilotumumab
Given IV
Other Names:
Drug: cisplatin
Given IV
Other Names:
Drug: pemetrexed disodium
Given IV
Other Names:
Other: laboratory biomarker analysis
Correlative studies
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To evaluate the progression-free survival of patients with malignant pleural mesothelioma (MPM) treated with anti-HGF monoclonal antibody AMG 102 in combination with pemetrexed disodium and cisplatin.
SECONDARY OBJECTIVES:
I. To assess the toxicity associated with this regimen in these patients. II. To determine the response rate of patients treated with this regimen. III. To determine the overall survival of patients treated with this regimen. IV. To evaluate multiple potential correlative biomarkers in MPM that are relevant to this combined regimen, including serum HGF and mesothelin levels, c-met expression by IHC in tumor specimens, presence of c-met mutations in tumor, and the presence of thymidylate synthetase (TS) and excision repair cross complementing protein-1 (ERCC1) polymorphisms.
OUTLINE: This is a multicenter study.
Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression. Some patients undergo blood sample collection at baseline and periodically during study for correlative biomarker studies. Tumor samples from diagnostic tissue may also be analyzed.
After completion of study therapy, patients are followed up periodically every 3 months for 2 years and then every 6 months for 1 year.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Histologically and cytologically confirmed malignant mesothelioma of the pleura
- All subtypes allowed
- Disease not amenable to curative surgery
-
Measurable disease
- Patients with disease not measurable by standard RECIST criteria (i.e., pleural rinds/thickening only) allowed
- Pleural effusions or positive bone scans are not considered measurable
- No prior radiotherapy to the target lesion or measurable lesion unless the site has subsequent evidence of progression
-
Patients who have undergone pleurodesis allowed
- Post-pleurodesis CT scan required
- No known or suspected brain metastases
- ECOG performance status 0-1
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 1.5 times ULN
- ALT and AST ≤ 1.5 times ULN
- Albumin ≥ 2.5 g/dL
- Creatinine clearance ≥ 45 mL/min OR serum creatinine ≤ 1.5 times ULN
- Able to take folic acid and vitamin B12
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must agree to use effective contraception
- No active infection or serious concomitant systemic disorder in compatible with the study
-
No thrombosis or vascular ischemic events within the last 12 months, including any of the following:
- Deep venous thrombosis
- Pulmonary embolism
- Transient ischemic attack
- Cerebral infarction
- Myocardial infarction
- No peripheral edema ≥ grade 3
- No serious or non-healing wounds
- No second primary malignancy except in situ carcinoma of the cervix or breast, other in situ malignancies, adequately treated basal cell carcinoma of the skin, or other malignancy within the past 3 years with no evidence of recurrence
- No concurrent antiretroviral therapy for HIV-positive patients
- At least 4 weeks since prior radiotherapy
-
More than 30 days since major surgery procedures or > 14 days since any minor surgical procedure and recovered
- Central venous catheter placement, fine-needle aspiration, thoracentesis, or paracentesis are not considered major or minor surgical procedures
- No prior systemic chemotherapy for mesothelioma
- No prior intracavity cytotoxic drugs or immunomodulators (unless for the purpose of pleurodesis)
- No prior anti-HGF monoclonal antibody AMG 102, other c-MET, or HGF inhibitors
-
No prior or concurrent anticoagulation therapy within the past 7 days
- Low-dose Coumadin-type anticoagulants or low-molecular weight heparin for prophylaxis against central venous catheter thrombosis allowed
- No investigational agents within the past 4 weeks
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01105390
| Principal Investigator: | James Stevenson | Eastern Cooperative Oncology Group |
More Information
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT01105390 History of Changes |
| Other Study ID Numbers: |
E1B09 NCI-2011-02068 ( Registry Identifier: CTRP (Clinical Trials Reporting System) ) U10CA021115 ( US NIH Grant/Contract Award Number ) CDR0000670445 ( Registry Identifier: PDQ (Physician Data Query) ) |
| Study First Received: | April 15, 2010 |
| Last Updated: | August 1, 2013 |
Additional relevant MeSH terms:
|
Mesothelioma Lung Neoplasms Adenoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Mesothelial Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases |
Cisplatin Pemetrexed Antibodies Antibodies, Monoclonal Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on June 22, 2017